How to Manage Estrogen on TRT

Your body is converting testosterone to estrogen right now, and that is not a problem. It is the system working exactly as designed.

But when men start testosterone replacement therapy and their estradiol comes back elevated on labs, the most common clinical response is to prescribe something called an aromatase inhibitor, which is a drug that blocks the enzyme responsible for that conversion. The logic seems straightforward: estrogen is high, block the thing making estrogen. What that logic misses is why estrogen was high in the first place, and what happens when you suppress it.

To understand why that matters, you need to see the whole system first.

You have an enzyme called aromatase, technically named CYP19A1, which is a cytochrome P450 enzyme that converts androgens into estrogens. Specifically it converts testosterone into estradiol, which is the form of estrogen most active in men. In men, roughly 80 percent of circulating estradiol does not come from your testes producing it directly. It comes from peripheral tissues throughout your body converting testosterone into it, with adipose tissue being the primary site. Your testes contribute about 20 percent. So most of your estrogen is made outside your gonads, through a conversion process that is running constantly in your fat cells.

That matters because aromatase expression is not fixed. It is regulated. And several factors push it up or down.

Adipose tissue drives the most aromatase activity because aromatase gene expression in fat cells is activated by glucocorticoids, inflammatory cytokines like TNF-alpha, and a class of signaling proteins called class 1 cytokines. When you carry more body fat, you have more of the tissue where aromatase is concentrated, and that tissue is expressing more of the enzyme because fat itself generates low-grade inflammation. A 2015 study by Chand and colleagues showed that weight gain and inflammation directly upregulate aromatase expression in male adipose tissue, so it is not just that heavier men have more fat cells doing normal amounts of conversion. The conversion rate per cell is also elevated.

The second major driver is something called substrate-driven conversion, which is what makes injection frequency so important.

Aromatase is an enzyme with a fixed capacity at any given moment, but its output increases when you flood it with raw material. Testosterone is that raw material. When you inject a large weekly dose of testosterone cypionate, which has an elimination half-life of about 4.5 days, your testosterone peaks within 24 to 48 hours after the injection. Estradiol trails that peak by about one to two days, climbing as aromatase processes the surge of available testosterone. By day seven you are in a trough. Then the cycle repeats.

That peak is the problem. A large bolus of testosterone hitting aromatase enzymes throughout your body all at once produces estradiol spikes that would not occur if the same total weekly dose was delivered in smaller amounts more frequently. Pharmacokinetic data published by Pastuszak and colleagues in 2022 showed that splitting a weekly dose into twice-weekly injections reduces peak-to-trough variance by approximately 30 percent. Daily injection reduces it further, more closely mimicking the body's natural production of about 6 to 7 milligrams of testosterone per day. Because the conversion is substrate-driven, smaller peaks mean less conversion per peak, even though the total weekly testosterone dose has not changed.

Beyond body fat and injection frequency, alcohol directly increases aromatase activity. Insulin resistance affects both aromatase expression and something called SHBG, which stands for sex hormone-binding globulin, a protein that binds testosterone in the blood and reduces how much of it is free to be converted. Cortisol drives aromatase expression through the same promoter pathway as glucocorticoids, which means chronic stress and poor sleep elevate conversion by increasing circulating cortisol. Systemic inflammation activates the same TNF-alpha pathways that upregulate adipose aromatase. And genetic variation in CYP19A1 creates baseline differences in how much aromatase activity any individual has regardless of lifestyle.

These are the levers. The problem is that prescribing an aromatase inhibitor ignores all of them and instead just suppresses the output.

The Finkelstein study published in the New England Journal of Medicine in 2013 ran a randomized controlled trial with 400 healthy men aged 20 to 50. Researchers used a drug called goserelin to shut down the men's natural testosterone production entirely, then gave them controlled testosterone doses either with or without anastrozole, which is the most commonly prescribed aromatase inhibitor in TRT settings. This design let them isolate what estrogen deficiency does independently, keeping testosterone present while blocking its conversion.

The results separated the effects of each hormone clearly. Androgen deficiency drove the loss of lean mass and strength. Estrogen deficiency primarily drove fat accumulation, with subcutaneous fat area increasing two to three times in groups where estrogen was suppressed. Both deficiencies contributed to sexual dysfunction, but blocking aromatase caused statistically significant decreases in sexual desire with a P value below 0.001 and significant declines in erectile function with a P value of 0.022, even when testosterone was present.

A separate double-blind randomized controlled trial published by Burnett-Bowie and colleagues in 2009 followed 69 men over age 60 for twelve months, giving half of them one milligram of anastrozole daily. Spinal bone mineral density decreased significantly in the anastrozole group, with a P value of 0.0014. Estradiol in that group dropped from roughly 15 to 12 pg/mL, a modest 20 percent reduction, and that was enough to produce measurable bone loss over one year.

This is the clinical trap. A weekly injection produces an estrogen spike from substrate-driven conversion. The patient reports symptoms like water retention, mood shifts, or nipple sensitivity. The clinic prescribes anastrozole. Estrogen drops, sometimes too far. Now the patient has joint pain, erectile dysfunction, low mood, and is accumulating body fat, which are the same symptoms TRT was supposed to fix, just arriving from the opposite direction. The clinic adjusts the anastrozole dose, the patient oscillates between too-high and too-low estrogen, and both parties are managing a drug-on-drug problem that started with a correctable protocol decision.

The practical approach starts with accurate measurement. Standard immunoassay estradiol tests are designed for female hormone ranges and can cross-react with other steroids in men, producing inaccurate readings. The accurate test for men is called LC-MS/MS, which stands for liquid chromatography tandem mass spectrometry, and it is the gold standard for measuring estradiol in a male hormonal context. For most men on standard TRT doses, a target range of 20 to 35 pg/mL is reasonable. Men on higher doses who feel well may be fine up to 40 to 60 pg/mL.

If estradiol is elevated on an accurate test, the next question is why, not what drug blocks it. Injection frequency is the first and most impactful lever if the patient is on weekly injections, because moving to twice weekly or more frequent dosing directly reduces the substrate spikes driving conversion. Body fat, insulin sensitivity, alcohol intake, stress, sleep, and inflammation are the others.

It should be said directly: the specific claim that switching injection frequency eliminates the need for an aromatase inhibitor has not been tested in a dedicated randomized controlled trial. The mechanism is well-established, the pharmacokinetics are well-established, and the logic connecting them is sound. But that specific outcome has not been isolated experimentally. There are cases where an aromatase inhibitor is genuinely appropriate, typically after lifestyle and protocol adjustments have been optimized and estradiol remains elevated on accurate testing.

The point is not that aromatase inhibitors are never warranted. The point is that prescribing one before asking what is driving the conversion treats a lab number instead of a system.

Estrogen in men is not a byproduct to be managed. It is part of the architecture. The enzyme that makes it is regulated by the same signals that govern inflammation, stress, and body composition. Managing estrogen on TRT means managing those signals first, and understanding that suppressing the output without addressing the inputs is where most of the downstream problems begin.

---

References

1. Finkelstein JS, Lee H, Burnett-Bowie SA, et al. 2013. Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men. New England Journal of Medicine, 36911, 1011-1022. Source
2. Burnett-Bowie SM, McKay EA, Lee H, Leder BZ. 2009. Effects of Aromatase Inhibition on Bone Mineral Density and Bone Turnover in Older Men with Low Testosterone Levels. Journal of Clinical Endocrinology and Metabolism, 9412, 4785-4792. Source
3. Pastuszak AW, et al. 2022. Pharmacokinetics of Testosterone Cypionate Delivered via Subcutaneous Autoinjector. Andrology. Source
4. Chand AL, et al. (2015). Weight gain and inflammation regulate aromatase expression in male adipose tissue. Journal of Steroid Biochemistry and Molecular Biology.
5. Bhasin S, Brito JP, Cunningham GR, et al. (2018). Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. JCEM, 103(5), 1715-1744.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness